Understanding Inter-Individual Variability in Monoclonal Antibody Disposition

Area of Science:

• Pharmacology
• Immunology
• Biotechnology

Background:

• Monoclonal antibodies (mAbs) represent a major class of therapeutic proteins.
• Significant inter-individual variability exists in mAb pharmacokinetics, impacting treatment efficacy.
• Mechanisms driving these subject differences remain incompletely understood.

Purpose of the Study:

• To review and analyze the mechanisms of antibody disposition.
• To identify and evaluate factors contributing to inter-individual variability in mAb pharmacokinetics.
• To assess the role of specific biological and clinical factors in mAb disposition.

Main Methods:

• Comprehensive review of in vitro, preclinical, and clinical studies.
• Analysis of the neonatal Fc receptor and Fc gamma receptors' roles (expression, polymorphism).
• Evaluation of target properties (expression, shedding, turnover, internalization, heterogeneity, polymorphism).
• Assessment of anti-drug antibodies, co-administered drugs, and disease influence.

Main Results:

• Fc receptor expression and polymorphism significantly affect mAb disposition.
• Target characteristics, including expression and heterogeneity, are key determinants of variability.
• Anti-drug antibodies, concomitant medications, and disease states contribute to pharmacokinetic differences.
• Population pharmacokinetic modeling identified relevant covariates influencing mAb exposure.

Conclusions:

• Multiple factors, including Fc receptors, target properties, and immunogenicity, drive inter-individual variability in mAb pharmacokinetics.
• Understanding these determinants is essential for optimizing therapeutic mAb efficacy and safety.
• Further research into these factors will enable more personalized therapeutic strategies.